Day traders, it's time to focus on Immuron Limited (IMRN:NASDAQ) as their stock price soars by a stunning 59.36% to $3.00 with a trading volume of 4.0M! This significant surge is in response to the FDA lifting the clinical hold on their groundbreaking Campylobacter ETEC Therapeutic, allowing for two Phase 2 clinical trials to commence. The trials, focusing on preventing infectious diarrhea caused by ETEC and protecting against moderate to severe campylobacteriosis, have the potential to revolutionize treatment for these common ailments. With infectious diarrhea being a major concern for travelers and military personnel alike, this innovative therapeutic may provide a much-needed solution to antibiotic resistance and post-infectious complications. As the trials progress, the IMRN stock is sure to attract attention from investors eager to capitalize on this exciting development in infectious disease treatment. Day traders, this is your chance to evaluate if the stock's current trend is justified and seize the opportunity to ride the wave of success with Immuron Limited!